BioSpace News Archive

RedHill Biopharma Ltd. announced that two oral presentations and two posters on two of the Company’s leading drug candidates, RHB-1051 and RHB-104 will be presented at the American College of Gastroenterology 2019 Annual Scientific Meeting, being held October 25-30, in San Antonio, Texas.

Leading Innovator in Non-Invasive Pain Relief to Expand Technology in VibraCool® Flex for Low Back Pain Sufferers

Edwards brings 20 years of global pharmacy and health care operations experience to Orlando-based specialty and home delivery pharmacy

Astellas Pharma Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of ASP1128 for patients at increased risk of developing moderate to severe acute kidney injury after coronary artery bypass and/or valve surgery.

EVERSANA™, the leading independent provider of commercial services to the life science industry, has been certified as a Great Place to Work® by the global authority in workplace culture.

Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of LILETTA®

HealthSnap, a leading digital and lifestyle health platform, and StrongPath™, a startup dedicated to addressing sarcopenia and other chronic diseases largely caused by inactivity, poor diet and other unhealthy behaviors, today announced a strategic partnership to leverage HealthSnap’s wellness and lifestyle data analytics platform

Prometheus Biosciences is committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.

DiscGenics, Inc., today announced that it has received the go-ahead from an independent data safety monitoring committee (DSMC) to enroll the final 24 patients in its first-in-human U.S. clinical study of IDCT, an allogeneic, injectable disc cell therapy for mild to moderate degenerative disc disease (DDD).

Celsius Holdings, Inc. (Nasdaq: CELH), maker of the leading global fitness drink, CELSIUS®, today announced that it completed the previously announced financial restructuring and acquisition of Func Food Group Oyj (“Func Food”) on October 25, 2019.